Join the Oncology Voice Network. Join for Free
Busting Silos: Building the Future of Oncology Drug Development

Busting Silos: Building the Future of Oncology Drug Development


Share This Article


Summary

In our premiere episode, Dr. Ramin Farhood, along with Dr. Kirk Shepard, shares the origin story behind the Oncology Voice Network (OVN)—a bold vision to unite pharma, biotech, academia, and advocacy, breaking down silos that have slowed progress for years.

What does it mean to give oncology drug development a “home”? 

 

In our premiere episode, Dr. Ramin Farhood, along with Dr. Kirk Shepard, shares the origin story behind the Oncology Voice Network (OVN)—a bold vision to unite pharma, biotech, academia, and advocacy, breaking down silos that have slowed progress for years.

 

Hear how the book ‘Voices of Oncology’ inspired conversations among industry leaders, and discover how those insights gave rise to a living, breathing network built on shared knowledge and real collaboration.

 

See how OVN is redefining what’s possible in cancer innovation. Listen to #OncologyVoiceNetwork now!

Watch on YouTube

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval
OVN Avatar Avi Cherla, MSc; Huseyin Naci, MHS, PhD; Aaron S. Kesselheim, MD, JD, MPH; Bishal Gyawali, MD, PhD; Elias Mossialos, MD, PhD

Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval

Podcast
Hiring Managers Beware: Reverse Rejection Explained!
Partner Avatar Michael Pietrack

Hiring Managers Beware: Reverse Rejection Explained!

Article
The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates
OVN Avatar Jamie Riley

The Talent Inflection Point in Pharma and Biotech: A Challenge to Companies — and a Call to Candidates

Article
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
OVN Avatar Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li

Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?

Article
New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures
OVN Avatar Forbes Books Press Release Official

New Book Unites Oncology’s Brightest Minds To Innovate Cancer Cures

Podcast
MSL Career Options: The transition from Field Medical to Medical Director
Partner Avatar MSL Talk: Tom Caravela, Josh Corriveau

MSL Career Options: The transition from Field Medical to Medical Director

Explore OVN